Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Market Whales and Their Recent Bets on AMGN Options
This Is What Whales Are Betting On Gilead Sciences
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
Cerevel Ticks Higher as AbbVie Says It Expects Deal to Close Soon
4 Stocks to Watch on Thursday: LUV, LINE and More
Biomarin Pharmaceutical Analyst Ratings
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
AbbVie in Charts: Skyrizi, Rinvoq Sales Jump, While Humira Revenue Falls ~30% Y/Y in Q2
Earnings Summary: AbbVie Reports Mixed Q2 Results; Raises FY24 EPS Outlook
AbbVie Non-GAAP EPS of $2.65 Misses by $0.01, Revenue of $14.46B Beats by $430M
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
United Therapeutics Analyst Ratings
BioMarin Gets Expanded FDA Approval for CLN2 Therapy Brineura
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Albemarle Is Out of Wells Fargo's Signature Picks
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
Biotech ETF (XBI) Rallied From the Blue Box Hitting Target
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial